Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Equity Average (2019 - 2023)

Alx Oncology Holdings' Equity Average history spans 5 years, with the latest figure at $190.7 million for Q3 2023.

  • For Q3 2023, Equity Average fell 36.77% year-over-year to $190.7 million; the TTM value through Sep 2023 reached $190.7 million, down 36.77%, while the annual FY2022 figure was $313.3 million, 20.98% down from the prior year.
  • Equity Average for Q3 2023 was $190.7 million at Alx Oncology Holdings, down from $226.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $424.2 million in Q1 2021 and bottomed at -$80.2 million in Q2 2020.
  • The 5-year median for Equity Average is $275.2 million (2022), against an average of $216.3 million.
  • The largest annual shift saw Equity Average skyrocketed 678.81% in 2021 before it tumbled 36.77% in 2023.
  • A 5-year view of Equity Average shows it stood at -$66.8 million in 2019, then skyrocketed by 610.32% to $340.9 million in 2020, then grew by 9.73% to $374.1 million in 2021, then fell by 26.44% to $275.2 million in 2022, then tumbled by 30.7% to $190.7 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Equity Average are $190.7 million (Q3 2023), $226.5 million (Q2 2023), and $251.9 million (Q1 2023).